Global Gene Therapy Market: Current Analysis and Forecast (2020-2027)

  • Single User - $3500
  • Multi User - $4900
  • Enterprise User - $6860
  • Buy Report

The gene therapy is the next trend of therapeutic modernization in the life sciences industry. These therapy approaches could help the enormous preponderance of newborns with different diseases. Gene therapy possesses the potential to transform medicine and establish opportunities for patients who are living with complicated, and even incurable, diseases. As scientists continue to make great strides in this therapy, FDA is committed to helping speed up the gene therapy development by timely review of pioneering therapies that have the potential to save lives. The gene therapy market is experiencing significant growth on account of surging prevalence of cancer and rare diseases. According to WHO, in the United States, over 400 products have been approved as therapy for more than 200 rare disease indications and in the EU, over 70 products for about 45 indications. Furthermore, in the field of molecular and cellular biology, rapid and important developments, led by technological advances in genomics and gene editing techniques, have contributed to a growing number of approved gene therapies and an expanding pipeline. According to the Alliance for Regenerative Medicine (ARM), by the end of the Q22019, there were more than 700 ongoing clinical trials globally. The American Medical Association reports that around 4,000 diseases have been linked to gene disorders (including cancers, AIDS, cystic fibrosis, and Parkinson's and Alzheimer's diseases). The successful treatment with gene therapy could positively affect millions of lives. The COVID-19 pandemic has disrupted worldwide management efforts around gene therapies. The manufacture and delivery of treatments, research and clinical development, and commercial operations are the three areas within the gene therapy sector which have been most interrupted amid COVID-19 crisis. The development of gene therapies has been less affected. For instance, Peter Marks, Director of FDA’s Center for Biologics Evaluation and Research (CBER) stated that with the influx of applications for cell and gene therapies over the last five years, it should have doubled in size while it is only modestly larger, 15-20% larger in size. Based on vector, the market is fragmented into viral and non-viral vectors. The viral vector segment generated revenue of US$ 3.1 billion in 2019. The market is expected to grow at a CAGR of 29.18% during the forecast period to reach a market valuation of US$ 17.9 billion by 2027 owing to the substantial advances in vector manufacturing, distribution, and security. Furthermore, the viral vector market is mainly bifurcated into the lentivirus, adeno-associated virus, retrovirus & gammaretrovirus, modified herpes simplex virus, and adenovirus. Based on gene type, the market is mainly fragmented into antigen, cytokine, tumor suppressor, suicide, deficiency, receptor, and others. The antigen segment dominated the market generating total revenue of US$ 0.7 billion in 2019 and is anticipated to maintain its dominance during the analyzed period. The gene therapy holds potential for treating various indications including oncology, rare diseases, cardiovascular, neurology, infectious and others. The oncology segment dominated the market and generated revenue of US$ 1.7 billion in 2019 owing to the increasing number of cancer cases. Cancer is the second leading cause of death worldwide, accounting for an estimated 9.6 million deaths, or 1 in 6 deaths, in 2018. Based on delivery method, the market is mainly disintegrated into in-vivo and ex-vivo. The ex-vivo segment is expected to grow at the highest CAGR of 35.5% during the forecast period owing to the benefit of expression of the gene and health of the transfected cells that can be verified before it is introduced to the patient. For a better understanding of the market penetration of the healthcare analytics market, the market is analyzed based on its worldwide presence in the countries such as North America (the U.S, Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, Australia, South Korea, and Rest of APAC), Rest of World. North America constitutes a major market for the gene therapy industry. Some of the major players operating in the market include Biogen, BioMarin Pharmaceuticals, bluebird bio, Bristol Myers Squibb, Gilead Sciences, Novartis, Orchard Therapeutics, Regenxbio, Spark Theraputics, and uniQure. The global gene therapy market was valued at US$ 3.5 billion in 2019 and is projected to expand significantly with a CAGR of 29.71% from 2021 to 2027. The global gene therapy market is expected to witness a boost, owing to the rising incidence of cancer and other diseases, growing gene therapy pipeline and increasing funding for the gene therapy research.

1 MARKET INTRODUCTION 1.1 Market Definitions 1.2 Objective of the Study 1.3 Limitation 1.4 Stake Holders 1.5 Currency Used in Report 1.6 Scope of the Global Gene Therapy Market Study 2 RESEARCH METHODOLOGY OR ASSUMPTION 2.1 Research Methodology for the Global Gene Therapy Market 2.1.1 Main Objective of the Global Gene Therapy Market 3 INDUSTRY PERFORMANCE 4 EXECUTIVE SUMMARY 5 TOP START-UPS UNDER GENE THERAPY SECTOR 6 COVID-19 IMPACT 7 MARKET INSIGHTS BY VECTOR 7.1 Viral Vector 7.1.1 Lentivirus 7.1.2 Adeno-Associated Virus 7.1.3 Retrovirus & Gammaretrovirus 7.1.4 Modified Herpes Simplex Virus 7.1.5 Adenovirus 7.2 Non-Viral Vector 8 MARKET INSIGHTS BY GENE TYPE 8.1 Antigen 8.2 Cytokine 8.3 Tumor Suppressor 8.4 Suicide 8.5 Deficiency 8.6 Receptor 8.7 Others 9 MARKET INSIGHTS BY INDICATION 9.1 Oncology 9.2 Rare Diseases 9.3 Cardiovascular 9.4 Neurology 9.5 Infectious 9.6 Others 10 MARKET INSIGHTS BY DELIVERY METHOD 10.1 In-vivo 10.2 Ex-vivo 11 MARKET INSIGHTS BY REGION 11.1 North America Gene Therapy Market 11.1.1 US 11.1.2 Canada 11.1.3 Rest of North America 11.2 Europe Gene Therapy Market 11.2.1 United Kingdom 11.2.2 France 11.2.3 Germany 11.2.4 Spain 11.2.5 Italy 11.2.6 Rest of Europe 11.3 Asia Pacific Gene Therapy Market 11.3.1 China 11.3.2 Japan 11.3.3 Australia 11.3.4 South Korea 11.3.5 Rest of Asia Pacific 11.4 Rest of World Gene Therapy Market 12 GENE THERAPY MARKET DYNAMICS 12.1 Marke Drivers 12.2 Market Challenges 12.3 Impact Analysis 13 LEGAL & REGULATORY FRAMEWORK 14 DEMAND AND SUPPLY SIDE ANALYSIS 14.1 Demand Side Analysis 14.2 Supply Side Analysis 14.2.1 Top Product Launches 14.2.2 Top Business Partnerships 14.2.3 Top Merger & Acquisitions 14.2.4 Top Business Expansions and Investments 15 VALUE CHAIN ANALYSIS 16 GENE THERAPY MARKET OPPORTUNITIES 17 GENE THERAPY MARKET TRENDS & INSIGHTS 18 COMPETITIVE SCENARIO 18.1 Porter’s Five forces analysis 18.1.1 Bargaining power of Supplier 18.1.2 Bargaining power of Buyer 18.1.3 Industry Rivalry 18.1.4 Availability of Substitute 18.1.5 Threat of new Entrants 18.2 Competitive Landscape 18.2.1 Company Shares, By Revenue 18.3 Competition Matrix 18.3.1 Product/Service Portfolio 18.3.2 Target Markets 18.3.3 Target End Users 18.3.4 Research & Development 18.3.5 Strategic Alliances 19 COMPANY PROFILED 19.1 bluebird bio 19.1.1 Key Facts 19.1.2 Business Description 19.1.3 Key Product/Services Offerings 19.1.4 Growth Strategy 19.1.5 SWOT Analysis 19.1.6 Key Financials 19.1.6.1 Revenue Split 19.1.6.2 Financial Overview of bluebird bio 19.1.7 Recent Developments 19.1.7.1 Product Launches 19.1.7.2 Partnerships 19.1.7.3 Business Expansion and Investments 19.1.7.4 Merger and Acquisition 19.2 Biogen 19.3 BioMarin Pharmaceuticals 19.4 Celgene Corporation 19.5 Gilead Sciences 19.6 Novartis 19.7 Orchard Therapeutics 19.8 Regenxbio 19.9 Spark Therapeutics 19.10 uniQure 20 DISCLAIMER

Related Reports

Protein Engineering Market Forecast till 2027

Protein Engineering Market: Information by Type (Instrument, Reagent, Services & Software), by Application (Food & Detergent Industries, Environmental, Medical, Biopolymer Production, Nano Biotechnology), by Method (Rational Protein Design and Directed Evoluti ... read more

Category: Pharmaceuticals and Healthcare
Published: Jan 2022
Pages: 132
Single user Price: $4450
Epilepsy Surgery Market Forecast till 2027

Epilepsy Surgery Market: Information by Procedure Type (Resective Surgery, Laser Interstitial Thermal Therapy (LITT),), by End User (Hospitals & Clinics, Specialty Centers) and by Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)—Forecast til ... read more

Category: Pharmaceuticals and Healthcare
Published: Jan 2022
Pages: 105
Single user Price: $4450
Disposable Nitrile Gloves Market Forecast 2027

Disposable Nitrile Gloves Market: Information by Type (Powder-free and Powdered), by Application (Medical and Non-medical), and by Region(Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2027 Market Overview The global disposable ... read more

Category: Pharmaceuticals and Healthcare
Published: Jan 2022
Pages: 91
Single user Price: $4450
Global Dental Software Market Forecast till 2027

Dental Software Market: Information by Type (Practice Management Software, Patient Communication Software, Treatment Planning Software, Patient Education Software, Dental Imaging Software), by Deployment (On-Premise, Web-Based, Cloud-Based), by End User (Denta ... read more

Category: Pharmaceuticals and Healthcare
Published: Jan 2022
Pages: 120
Single user Price: $4450
Global Dental industry Market Research Report—Forecast till 2027

Market Synopsis:
Global Dental Industry Market is anticipated to exhibit a CAGR of 5.28% during the forecast period of 2020 to 2027, to surpass USD 42,244.27 Million by 2027. The increasing dental caries in children and adults are expected to drive t ... read more

Category: Pharmaceuticals and Healthcare
Published: Jan 2022
Pages: 490
Single user Price: $4450